Parallax Volatility Advisers
LRMR icon

Parallax Volatility Advisers’s Larimar Therapeutics LRMR Stock Holding History

Parallax Volatility Advisers’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5,500
Closed -$308K – 3239
2017
Q1 		$308K Buy
+5,500
New +$273K ﹤0.01% 1748

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Parallax Volatility Advisers's LRMR Position: Q2 2017 in Review

Parallax Volatility Advisers sold out of Larimar Therapeutics (LRMR) in Q2 2017, closing a stake of 269 shares — an estimated $15K sold.

Parallax Volatility Advisers first reported a position in LRMR in Q4 2016 and held it in 2 quarters. The position peaked at $21K in Q4 2016. 69 funds tracked by Wall St. Rank hold LRMR as of Q2 2017.

  • Parallax Volatility Advisers reported no remaining Larimar Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Parallax Volatility Advisers sold 269 Larimar Therapeutics shares in Q2 2017, an estimated $15K.
  • Parallax Volatility Advisers first reported a position in Larimar Therapeutics in Q4 2016 and held it in 2 quarters.
  • Parallax Volatility Advisers's Larimar Therapeutics position peaked at $21K in Q4 2016.
  • 69 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2017.

Based on Parallax Volatility Advisers's 13F filing for Q2 2017, filed 14 Aug 2017.